半剂量依那西普联合甲氨蝶呤治疗强直性脊柱炎髋关节病变的临床观察  

Half-value dose Etanercept combined with Methotrexate in the therapy of hip joint lesion of ankylosing spondylitis

作　　者：叶静华[1] 蔡小燕[1] 林小军[1] 唐莼[1] 余纳[1] 李伟念[1] 何志翔[1] 

机构地区：[1]广州市第一人民医院风湿免疫内科,广东广州510180

出　　处：《中国现代医生》2012年第18期69-71,共3页China Modern Doctor

摘　　要：目的观察半剂量依那西普联合甲氨蝶呤治疗强直性脊柱炎(AS)髋关节病变的疗效。方法对25例伴单侧或双侧髋关节受累的AS患者给予半剂量依那西普25 mg,皮下注射,每周1次,持续12周,并联合甲氨蝶呤15 mg,口服或皮下注射,每周1次。观察参数包括治疗前后的Harris髋关节评分、AS疾病活动度评分(ASDAS)和Bath AS髋关节X线指数(BASRI-hip)。结果 25例患者中共33个髋关节受累,其治疗前Harris髋关节评分为(50.79±14.52)分,治疗12周后评分明显上升为(79.97±15.54)分(P<0.01);治疗前ASDAS评分为(4.76±0.69)分,治疗12周后明显下降为(2.62±0.50)分(P<0.01);而BASRI-hip治疗前后无明显改变。本研究治疗和随访过程中患者未出现结核和其他严重感染。结论半剂量依那西普联合甲氨蝶呤治疗AS相关髋关节病变有效,未见明显不良反应。Objective To observe the therapeutic effect of half-value dose Etanercept combined with Methoterxate （MTX） in hip joint lesion of ankylosing spondylitis （AS）. Methods Twenty-five patients with AS with unilateral or bilateral hip joint lesion were enrolled in the study. These patients received Etanereept 25 mg injected subcutaneously once a week for 12 weeks, combined with MTX 15 mg once a week administrated orally or subcutaneously. Parameters observed included Har- ris hip score, ankylosing spondylitis disease activity score （ASDAS）, Bath ankylosing spondylitis radiologic index-hip（BAS- RI-hip） before and after the treatment. Results Thirty-three hip joints were enrolled in 25 patients. Harris hip score were elevated significantly from （50.79±14.52） before treatment to （79.97±15.54） after treatment （P 〈 0.01） while ASDAS declined from （4.76±0.69） to （2.62±0.50）（P 〈 0.01）. But there was no change in BASRI-hip before and after treatment. During the treatment and follow-up period, no tuberculosis or severe infection was observed. Conclusion Half-value dose Etanercept combined with Methotrexate is effective in treating hip joint lesion of AS without serious side effects.

关 键 词：强直性脊柱炎 髋关节病变 依那西普 半剂量 

分 类 号：R9[医药卫生—药学]